Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold.

Blueprint Medicines downgraded at TD Cowen

A doctor examining a patient’s samples in a modern hospital setting.

This modification comes after Sanofi declared its intention to buy Blueprint Medicines Corporation (NASDAQ:BPMC). The equity value of the transaction is $9.1 billion, with the possibility for a contingent value of $9.5 billion.

Frahm has set a price target of $130 for BPMC in response to this acquisition news. Since it fits with Sanofi’s larger strategic goals, this development represents a significant shift for Blueprint Medicines Corporation (NASDAQ:BPMC).

Nonetheless, in Q1 of 2025, the company has shown outstanding commercial momentum, as seen by AYVAKIT revenue growing 61% year over year due to systemic mastocytosis’s high acceptance. The business raised its AYVAKIT net product revenue forecast for the entire year to $700-$720 million, citing excellent market conditions and performance.

Over 95% of patients are satisfied with AYVAKIT, and since its approval for indolent systemic mastocytosis, the number of prescribers has tripled.

While we acknowledge the potential of BPMC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BPMC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.